Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of elexacaftor and bamocaftor on the metabolic and thermal stability of the F508del-CFTR protein in human airway epithelial cells.

American journal of physiology. Lung cellular and molecular physiology - 1 Nov 2025

Carrez Thomas, Mirval Sandra, Barrault Christine, Devetter Florian, Vandebrouck Clarisse, Becq Frédéric

Abstract excerpt

Trikafta (elexacaftor/tezacaftor/ivacaftor; ETI) is approved for cystic fibrosis (CF) patients with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or another responsive mutation based on in vitro data. However, the pharmacological effects of ETI on F508del-CFTR remain incompletely defined in vitro. To explore the mechanisms underlying Trikafta's clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bronchi

Share to Drug Combinations

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Share to Quinolones

Source

Identifiers

PMID: 40803756
DOI: 10.1152/ajplung.00011.2025

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of elexacaftor and bamocaftor on the metabolic and thermal stability of the F508del-CFTR protein in human airway epithelial cells.PMID 40803756Read ↗

Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.Semantic proximity Read ↗

The New and Advanced Cystic fibrosis transmembrane conductance regulators Modulators in Children with Cystic Fibrosis: A Narrative Review on Long-Term Outcomes, Recent Advances, and Comparative Insights.Semantic proximity Read ↗

The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.Semantic proximity Read ↗

Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational StudySemantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.Semantic proximity Read ↗

Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor (ETI) suggest benefits beyond improved CFTR channel functionSemantic proximity Read ↗

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).Semantic proximity Read ↗

Cystic fibrosis airway inflammation enables elexacaftor/tezacaftor/ivacaftor-mediated rescue of N1303KCFTRmutationSemantic proximity Read ↗

Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges.Semantic proximity Read ↗

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.